“We have obtained guarantees that opera will remain and develop in France,” Armand said. “Our demands regarding employment, production and investment will be respected.”
The deal has been highly controversial in France, with politicians warning that it could threaten manufacturing jobs and undermine Europe’s efforts to secure vital pharmaceutical supply chains. There is.
However, as previously reported, the French government is keen on the deal.
Economy Ministry officials told reporters Sunday night that the Paris government had obtained “the highest possible level of guarantees” from the companies in the tripartite contract, which includes Sanofi, CD&R and the government. The official spoke on condition of anonymity in line with French government communications policy.
“Blocking the deal would not have provided greater assurance,” the official said, adding that foreign buyers would bring “new investment capital” seen as essential for the development of France’s pharmaceutical manufacturing sector. He pointed out that this would happen.
The official confirmed that the government will conduct an investment review on the acquisition in the future.
Armando Industry Minister Marc Ferracci is expected to announce details of the agreement reached between Sanofi and the American buyer on Monday.
